Kenvue Inc
Company Profile
Business description
Kenvue is the world’s largest pure-play consumer health company by sales, generating $15 billion in annual revenue. Formerly known as Johnson & Johnson’s consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of silos within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women’s health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson’s, Aveeno, and Neutrogena. Despite playing in a fragmented industry with intense competition and changing consumer preferences, many of Kenvue’s brands are the global leader in their respective segment thanks to their strong brand power.
Contact
199 Grandview Road
SkillmanNJ08558
USAT: +1 908 874-1200
Sector
Consumer Defensive
Stock type
Defensive
Industry
Household & Personal Products
Fiscal Year End
31 December 2025
Employees
22,000
Kenvue Inc News & Analysis
stocks
9 best US dividend aristocrats to buy now
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,420.90 | 57.90 | -0.68% |
| CAC 40 | 8,199.71 | 88.08 | 1.09% |
| DAX 40 | 23,147.02 | 595.59 | 2.64% |
| Dow JONES (US) | 43,191.24 | 649.67 | -1.48% |
| FTSE 100 | 8,871.31 | 61.57 | 0.70% |
| HKSE | 22,977.61 | 28.66 | -0.12% |
| NASDAQ | 18,350.19 | 497.09 | -2.64% |
| Nikkei 225 | 37,196.72 | 588.75 | -1.56% |
| NZX 50 Index | 12,469.71 | 80.34 | -0.64% |
| S&P 500 | 5,849.72 | 104.78 | -1.76% |
| S&P/ASX 200 | 8,198.10 | 47.60 | -0.58% |
| SSE Composite Index | 3,321.77 | 4.85 | 0.15% |